50
Participants
Start Date
August 1, 2022
Primary Completion Date
December 4, 2023
Study Completion Date
March 1, 2024
Dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories
Escalating doses of 1 mg (0.1%)、2.5mg (0.25%)、5 mg (0.5%)、10mg (1%)、15 mg (1.5%);single dose administration;topical vaginal suppository ;multiple-dose administration after single dose administration a 3-day wash out period ; once-daily for 6 consecutive days;
Placebo dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories
Dose 1、2、3、4 and 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories respective placebos;single dose administration;topical vaginal suppository ;multiple-dose administration after single dose administration a 3-day wash out period ; once-daily for 6 consecutive days;
RECRUITING
Q-Pharm Pty. Ltd, Brisbane
Protelight Pharmaceuticals Australia PTY LTD
INDUSTRY